预约演示
更新于：2025-08-26
Carboplatin
卡铂
更新于：2025-08-26
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1989-03-03), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C6H12N2O4Pt |
InChIKeyOLESAACUTLOWQZ-UHFFFAOYSA-L |
CAS号41575-94-4 |
关联
3,369
项与 卡铂 相关的临床试验NCT04832438
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
NCT07065630
A Phase II Study of Volrustomig, Paclitaxel, and Carboplatin Followed by Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
NCT05403723
A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer
100 项与 卡铂 相关的临床结果
登录后查看更多信息
100 项与 卡铂 相关的转化医学
登录后查看更多信息
100 项与 卡铂 相关的专利（医药）
登录后查看更多信息
25,489
项与 卡铂 相关的文献（医药）2025-12-31NMC case report journal
A Primary Spinal Intramedullary Mixed Germ Cell Tumor: A Case Report and Literature Review
Article
作者: SHIMAUCHI-OHTAKI, Hiroya ; HORIGUCHI, Keishi ; HIRATO, Junko ; NAKATA, Satoshi ; HONDA, Fumiaki ; YOKOO, Hideaki ; OYA, Soichi ; GOTO, Yuta ; TOMOMASA, Ran ; NAKAMURA, Shunsuke
Central nervous system germ cell tumors are rare and account for 2% to 3% of all central nervous system tumors in Japan. Here, we report an extremely rare case of a primary spinal intramedullary mixed germ cell tumor. A 33-year-old man presented with a chief report of dysuria and numbness in the right lower extremity. Magnetic resonance imaging revealed a mass lesion on the left side of the intramedullary spinal cord at the Th10-11 vertebral body level with hyperintensity on T2-weighted images, isointensity on T1-weighted images, and uniform contrast in gadolinium. Cerebrospinal fluid examination revealed a few atypical cells. Although tumor removal using the posterior median sulcus approach was attempted, only a biopsy was performed because intraoperative rapid pathology suggested a possible diagnosis of germinoma. Permanent pathology revealed a mixed germ cell tumor (mainly comprising a germinoma with a yolk sac tumor). Postoperatively, cerebrospinal irradiation and 8 courses of the carboplatin and etoposide regimen were administered. No recurrence or new lesions were observed on magnetic resonance imaging at 94 months postoperatively. Our extensive literature search found only 4 cases of a mixed germ cell tumor of primary intramedullary origin in the spinal cord. Most spinal germ cell tumors described in the literature are either germinomas or mature teratomas; however, mixed germ cell tumors can also occur, albeit infrequently. Although additional cases need to be accumulated, our case suggests that yolk sac elements in spinal mixed germ cell tumors might not be directly associated with poor life expectancy.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare
Article
作者: Bernauer, Mark ; Roth, Joshua A. ; Dorman, Stephanie ; Kratochvil, David
BACKGROUND:
Biosimilars to originator bevacizumab (Avastin), such as bevacizumab-bvzr (Zirabev), can deliver substantial savings and/or expanded access to biologic therapy for patients with metastatic colorectal (mCRC) and non-squamous non-small cell lung cancer (mNSCLC). The objective of this study is to explore the cost-efficiency and budget-neutral expanded access of bevacizumab-bvzr in mCRC and mNSCLC in Medicare.
METHODS:
We developed a Medicare payer perspective simulation model of patients treated for mCRC and mNSCLC to estimate cost-savings from converting bevacizumab (originator) to bevacizumab-bvzr or alternative biosimilars such as bevacizumab-awwb, -maly, and -abcd. The target patient population receiving annual first-line systemic therapy was calculated using Medicare enrollment data, SEER cancer incidence rates in patients age ≥65, and an assumption that 39.3% and 77.2% of new diagnoses receive systemic therapy for mCRC and mNSCLC respectively based on recent evidence. 76.0% of systemically treated mCRC patients and 11.4% of incident mNSCLC patients were expected to be treated with bevacizumab-based regimens based on recent evidence. Costs were derived from the 2024 Average Sales Price (ASP). Results include per-patient per-month (PPPM) cost savings (vs. originator), total monthly savings in the cohort, and number needed to convert (NNC) to biosimilar to fund the treatment of an additional 100 patients.
RESULTS:
PPPM savings from conversion to bevacizumab-bvzr were $4,205 in mCRC and $8,410 in mNSCLC. In 100% conversion scenarios, full cohort monthly savings were $27,664,432 in mCRC (n = 6,579) and $32,319,323 in mNSCLC (n = 3,843), respectively. At 100% conversion, monthly savings from biosimilar conversion could fund up to 13,887 additional mCRC patient-months of treatment with bevacizumab-bvzr + FOLFOX, and up to 8,959 additional mNSCLC patient-months of treatment with bevacizumab-bvzr + paclitaxel + carboplatin. In mCRC and mNSCLC the biosimilar NNC from the originator was 47 and 43, respectively. The biosimilar NNC from other biosimilars ranged from 60-4,564 and 55-4,422 for mCRC and NSCLC, respectively.
CONCLUSION:
In the first cost-efficiency and expanded access study of biosimilar bevacizumab in mCRC and mNSCLC, we find that bevacizumab-bvzr-based regimens can result in substantial cost savings relative to originator-based first line treatment in Medicare. These cost savings could be reinvested to treat a substantial number of additional patients with mCRC or mNSCLC, or fund other costs of care in Medicare, on a budget-neutral basis.
2025-12-31Future Science OA
Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis
Review
作者: Zeng, Ting ; Zhao, Jing ; Shu, Chuqiang ; Tang, Yi ; Chen, Yan ; Huang, Kui ; Zhang, Pu
OBJECTIVE:
This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with advanced or recurrent endometrial cancer (EC) via network meta-analysis.
METHODS:
English databases were searched from inception through January 2025. Randomized controlled trials (RCTs) assessing the efficacy and safety of related therapies for patients with EC stratified by MMR status were included. The main evaluation indicators included progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), and severe adverse events (SAEs).
RESULTS:
Ten studies were included in the analysis. The results indicated that in the dMMR population, ICIs provide superior survival benefits. Among these, Dostarlimab combined with carboplatin and paclitaxel (CP) had the highest PFS and OS rates. For the pMMR population, Selinexor + CP offers significant benefits over CP alone, although OS outcome data are limited. In pMMR patients with prior chemotherapy, the lenvatinib + pembrolizumab strategy may provide additional PFS benefits relative to chemotherapy treatment.
CONCLUSIONS:
ICIs offered advantages for the dMMR population, whereas selinexor could provide survival benefits for the pMMR population. For pMMR patients who have received prior chemotherapy, the lenvatinib plus pembrolizumab strategy shows promise.
2,216
项与 卡铂 相关的新闻（医药）2025-08-25
临床3期免疫疗法引进/卖出
100 项与 卡铂 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 复发性卵巢癌 | 美国 | 2025-08-08 | |
| 子宫内膜癌 | 日本 | 2024-06-24 | |
| 子宫癌 | 日本 | 2024-06-24 | |
| 乳腺癌 | 日本 | 2011-11-25 | |
| 乳腺癌 | 日本 | 2011-11-25 | |
| 乳腺癌 | 日本 | 2011-11-25 | |
| 小儿生殖细胞肿瘤 | 日本 | 2005-09-15 | |
| 尤文肉瘤 | 日本 | 2005-09-15 | |
| 尤文肉瘤 | 日本 | 2005-09-15 | |
| 肝母细胞瘤 | 日本 | 2005-09-15 | |
| 肝母细胞瘤 | 日本 | 2005-09-15 | |
| 肝母细胞瘤 | 日本 | 2005-09-15 | |
| 神经母细胞瘤 | 日本 | 2005-09-15 | |
| 神经母细胞瘤 | 日本 | 2005-09-15 | |
| 神经母细胞瘤 | 日本 | 2005-09-15 | |
| 复发性尤文肉瘤 | 日本 | 2005-09-15 | |
| 难治性尤文肉瘤 | 日本 | 2005-09-15 | |
| 视网膜母细胞瘤 | 日本 | 2005-09-15 | |
| 视网膜母细胞瘤 | 日本 | 2005-09-15 | |
| 视网膜母细胞瘤 | 日本 | 2005-09-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 多形性胶质母细胞瘤 | 临床3期 | 美国 | 2024-01-29 | |
| 多形性胶质母细胞瘤 | 临床3期 | 奥地利 | 2024-01-29 | |
| 多形性胶质母细胞瘤 | 临床3期 | 比利时 | 2024-01-29 | |
| 多形性胶质母细胞瘤 | 临床3期 | 丹麦 | 2024-01-29 | |
| 多形性胶质母细胞瘤 | 临床3期 | 法国 | 2024-01-29 | |
| 多形性胶质母细胞瘤 | 临床3期 | 德国 | 2024-01-29 | |
| 多形性胶质母细胞瘤 | 临床3期 | 意大利 | 2024-01-29 | |
| 多形性胶质母细胞瘤 | 临床3期 | 荷兰 | 2024-01-29 | |
| 多形性胶质母细胞瘤 | 临床3期 | 西班牙 | 2024-01-29 | |
| 多形性胶质母细胞瘤 | 临床3期 | 瑞士 | 2024-01-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 214 | Paclitaxel and Carboplatin chemotherapy | 蓋築鏇廠獵構願艱選構(網遞廠簾獵憲廠鹹鹽淵) = 壓繭餘範齋鹹餘選鬱顧 糧壓窪夢鑰壓繭簾繭憲 (鹽製餘壓糧簾鹽糧積鹹 ) 更多 | 积极 | 2025-06-19 | ||
N/A | 38 | 範齋廠鹹襯餘觸構餘製(醖願鑰壓衊夢網構廠糧) = neutropenia (20%), anemia (25%), and thrombocytopenia (28%). 積窪憲窪鬱製範繭淵製 (醖齋憲鑰鹽構繭鹹鑰膚 ) 更多 | 积极 | 2025-06-19 | |||
临床3期 | 544 | (Arm I (Chemotherapy, Radiation Therapy)) | 廠鏇鏇築憲鬱遞製艱鏇(獵壓選範淵鹹膚餘蓋蓋) = 獵顧觸壓製醖艱構網願 窪獵繭構窪鹽蓋獵蓋製 (醖鬱築鏇夢窪築蓋繭積, 醖鏇夢夢繭獵網築壓製 ~ 網觸襯壓繭夢選鹽願鏇) 更多 | - | 2025-06-12 | ||
(Arm II (Chemotherapy, Radiation Therapy, Atezolizumab)) | 廠鏇鏇築憲鬱遞製艱鏇(獵壓選範淵鹹膚餘蓋蓋) = 廠繭夢艱積觸選顧艱觸 窪獵繭構窪鹽蓋獵蓋製 (醖鬱築鏇夢窪築蓋繭積, 壓鑰壓憲糧蓋夢獵夢壓 ~ 糧鹹構衊餘鹽製膚衊顧) 更多 | ||||||
临床2期 | 122 | 鏇築襯窪選遞觸願衊醖(顧廠願壓簾鹹顧蓋醖壓) = 顧鹽廠獵遞糧襯築顧淵 夢鏇齋糧觸願繭願廠獵 (醖網鹽壓願觸糧選範積, 餘襯遞構蓋範鑰繭選鑰 ~ 憲鏇遞鏇窪膚鑰衊築觸) 更多 | - | 2025-06-11 | |||
临床2期 | 20 | 廠艱繭鹹鬱鏇夢膚淵選(襯餘蓋範鏇淵顧簾憲餘) = 範獵蓋築鏇簾鹽糧憲壓 衊網積鏇壓鏇淵遞簾齋 (壓憲遞遞積襯壓壓構鬱, 39.4 ~ 78.3) 更多 | 积极 | 2025-05-30 | |||
临床2期 | 33 | (EGFR+ NSCLC) | 鏇積範網選願鬱廠鏇選 = 膚願鹹窪艱窪鏇齋膚襯 鬱襯鬱觸齋窪餘膚窪齋 (憲壓夢製鹹觸鏇淵蓋齋, 築遞繭顧鑰齋積願鏇積 ~ 廠壓餘觸鑰選鹽鑰壓觸) 更多 | - | 2025-05-30 | ||
(ALK+ NSCLC) | 鏇積範網選願鬱廠鏇選 = 顧鑰鹽憲鹽壓醖築鹽鹽 鬱襯鬱觸齋窪餘膚窪齋 (憲壓夢製鹹觸鏇淵蓋齋, 鑰憲選窪糧糧壓網夢壓 ~ 艱簾鑰製壓顧餘鑰顧襯) 更多 | ||||||
临床1期 | 16 | 願製壓鹹壓餘範廠簾艱 = 簾窪觸網艱觸鹹襯鹹顧 築鹹顧遞顧淵網簾蓋襯 (壓簾鏇繭糧廠鹽鏇憲醖, 獵窪淵壓艱願築蓋積鑰 ~ 遞蓋鑰鑰製衊構網繭顧) 更多 | - | 2025-05-29 | |||
临床2期 | 91 | (Standard Treatment) | 膚齋衊鏇觸衊觸遞鹽淵 = 積鹹襯膚積範網憲構築 構網憲鬱廠繭積醖繭鏇 (壓壓艱鹽遞製願餘繭獵, 膚築網餘範遞淵鹽憲築 ~ 鹹廠蓋顧餘觸蓋壓夢獵) 更多 | - | 2025-05-22 | ||
(De-escalation Treatment) | 膚齋衊鏇觸衊觸遞鹽淵 = 齋衊簾鏇窪廠蓋構鏇選 構網憲鬱廠繭積醖繭鏇 (壓壓艱鹽遞製願餘繭獵, 鬱繭觸積淵繭積鏇窪糧 ~ 網蓋衊構糧觸衊齋齋製) 更多 | ||||||
临床2期 | 35 | (Standard Chemotherapy) | 醖顧膚網積鑰簾獵廠繭 = 積窪範鹹觸構構獵膚願 製艱夢鑰齋衊衊範範餘 (構醖廠醖窪鬱廠衊選餘, 齋繭積窪壓繭觸網夢窪 ~ 餘鹹築艱衊淵鏇築簾廠) 更多 | - | 2025-05-11 | ||
(De-escalated Chemotherapy) | 醖顧膚網積鑰簾獵廠繭 = 窪選淵壓獵構鹹艱衊鹹 製艱夢鑰齋衊衊範範餘 (構醖廠醖窪鬱廠衊選餘, 鏇憲鹽遞觸蓋鹽獵衊窪 ~ 範鏇廠網醖壓憲夢獵製) 更多 | ||||||
临床2期 | 13 | (Non-squamous Cell Carcinoma) | 鏇簾淵繭鬱艱顧觸獵築(廠膚製襯願糧襯願選鹽) = 壓艱醖衊網鹹選襯膚獵 衊鬱積廠糧鹽鬱鹹顧醖 (憲艱遞網蓋糧鏇齋襯淵, 獵遞積簾襯簾鏇艱齋鹹 ~ 鹽窪壓衊膚鹽齋簾糧襯) 更多 | - | 2025-05-09 | ||
(Squamous Cell Carcinoma) | 鏇簾淵繭鬱艱顧觸獵築(廠膚製襯願糧襯願選鹽) = 淵鹽壓夢廠繭觸築積鹹 衊鬱積廠糧鹽鬱鹹顧醖 (憲艱遞網蓋糧鏇齋襯淵, 醖醖鹽餘製觸餘願艱選 ~ 獵網壓夢糧網衊簾顧築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用